Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | USP5 | P45974 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10063407 | 0.83 | L3MBTL1 (0.42) | L3MBTL3L3MBTL1ALDH1A1LMNATP53 | |
| SCHEMBL20160890 | 0.79 | L3MBTL3 (0.42) | L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL7320872 | 0.79 | L3MBTL3 (0.45) | L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL81624 | 0.78 | L3MBTL1 (0.39) | L3MBTL3L3MBTL1ALDH1A1PIM1ACHE | |
| SCHEMBL18372271 | 0.78 | HRH3 (0.38) | TP53HRH3KCNH2 | |
| SCHEMBL10538464 | 0.77 | L3MBTL3 (0.44) | L3MBTL3L3MBTL1ALDH1A1HRH3 | |
| SCHEMBL7314532 | 0.77 | L3MBTL3 (0.44) | L3MBTL3L3MBTL1ALDH1A1HRH3 | |
| SCHEMBL131020 | 0.76 | MAPK1 (0.47) | L3MBTL3L3MBTL1GRIN2BALDH1A1LMNA | |
| SCHEMBL2285939 | 0.76 | BRD4 (0.38) | L3MBTL3L3MBTL1GRIN2BMAPK1 | |
| SCHEMBL3436969 | 0.76 | L3MBTL1 (0.46) | L3MBTL3L3MBTL1ALDH1A1PIM1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200262812-A1 | 4, 5, 6-TRI-SUBSTITUTED INDAZOLES DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN MEDICINES | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-08-20 | — | — | US | disclosed |
| EP-3441388-A1 | 4,5,6-TRI-SUBSTITUTED INDAZOLES DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2019-02-13 | — | — | EP | disclosed |
| EP-2109611-B1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MAN CO LTD (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-8178552-B2 | 7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178552-B2 | 7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178552-B2 | 7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2125801-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | Eisai R&D Management Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-2109611-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | Eisai R&D Management Co., Ltd. (JP) | 2009-10-21 | — | — | EP | disclosed |
| WO-2008095944-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008095944-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008095943-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPK13, MAPKAPK5 | L3MBTL3 4567/4885L3MBTL1 4739/4885GRIN2B 1089/4885 |
| US-20200262812-A1 | 4, 5, 6-TRI-SUBSTITUTED INDAZOLES DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN MEDICINES | CYP3A4, CYP4B1, CYP3A7 | L3MBTL3 3473/4885L3MBTL1 3549/4885GRIN2B 4248/4885 |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPKAPK5, MAPK13 | L3MBTL3 4480/4885L3MBTL1 4629/4885GRIN2B 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.